MRK Stock Analysis — Merck & Co.
Sector: Healthcare
AI Verdict
Merck trades at 19.5x next year’s earnings with a massive 456.5% EPS rebound expected—cheap for the growth if its patent moat holds, but the high RSI signals real pullback risk if the pipeline stumbles.
Competitive Moat
Merck's defensibility comes from its deep patent portfolio in oncology and vaccines, especially the blockbuster cancer drug Keytruda, which enjoys years of exclusivity. Its entrenched R&D engine and global regulatory expertise make it hard for rivals to replicate its pipeline at scale.
Summary
Analysts expect Merck's earnings to surge 456.5% next year, resetting its valuation after a year of high spending and patent cliffs.
Where It Stands
Merck is up 61.31% over the past year with an RSI of 66.9 (elevated) and trades at 19.5x next year's earnings, a discount to the 22x healthcare median, but its trailing P/E of 108.5x shows how much is riding on the rebound.
Key Metrics
- RSI: 66.9 — Near Overbought
- Trailing P/E: 108.5x
- Forward P/E: 19.5x
- PEG Ratio: 0.24
- Earnings Growth: +4.6%
- Revenue Growth: +0.0%
- Market Cap: $335.1B
- Dividend Yield: 0.03%
- 1-Year Return: 61.31%
- 52-Week High: $135.68
- 52-Week Low: $77.58
Analyst Consensus
25 Buy · 11 Hold · 0 Sell (36 analysts)
Bull Case
If Merck delivers the forecasted 456.5% EPS growth, you’re paying 19.5x forward earnings for a pipeline that could justify a much higher multiple.
Bear Case
With RSI at 66.9, the stock is at elevated levels, so even a modest pullback to a neutral RSI could mean a 10–15% drop from here if sentiment cools before the earnings rebound materializes.
Catalyst to Watch
Watch for upcoming clinical trial results and FDA approvals for new oncology drugs, as positive data could cement the expected earnings surge.